Calithera Biosciences Inc.

2.60+0.0100+0.39%Vol 96.52K1Y Perf 21.60%
Jun 24th, 2022 16:00 DELAYED
BID2.59 ASK2.75
Open2.64 Previous Close2.59
Pre-Market- After-Market2.73
 - -  0.13 5.00%
Target Price
33.33 
Analyst Rating
Moderate Buy 1.67
Potential %
1.18K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/50 
Value Ranking
     39.30
Insiders Value % 3/6/12 mo.
-/-/77 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/77 
Income Ranking
 —    -
Price Range Ratio 52W %
0.61 
Earnings Rating
Strong Buy
Market Cap12.64M 
Earnings Date
4th Aug 2022
Alpha-0.06 Standard Deviation0.20
Beta1.63 

Today's Price Range

2.542.74

52W Range

2.3149.80

5 Year PE Ratio Range

-4.20-3.90

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-3.70%
1 Month
1 227.21%
3 Months
391.03%
6 Months
261.11%
1 Year
21.60%
3 Years
-30.48%
5 Years
-82.95%
10 Years
-

TickerPriceChg.Chg.%
CALA2.600.01000.39
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
ValuationValueIndustryS&P 500US Markets
-0.10
3.07
26.93
14.70
-0.20
-15.99
-4.19
-0.65
-28 830 000.00
Forward PE-0.36
PEG-
Financial StrengthValueIndustryS&P 500US Markets
3.90
4.20
0.17
0.36
-3 121.40
Leverage Ratio 1.90
ProfitabilityValueIndustryS&P 500US Markets
-
-590.90
-588.20
-
-
RevenueValueIndustryS&P 500US Markets
9.75M
0.10
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-3.40-3.60-5.88
Q04 2021-5.60-4.8014.29
Q03 2021-4.60-3.0034.78
Q02 2021-4.60-3.8017.39
Q01 2021-5.40-5.60-3.70
Q04 2020-0.32-0.320.00
Q03 2020-0.31-0.32-3.23
Q02 2020-0.33-0.2912.12
Earnings Per EndEstimateRevision %Trend
6/2022 QR-2.7010.00Positive
9/2022 QR-2.6013.33Positive
12/2022 FY-11.700.85Positive
12/2023 FY-7.1513.86Positive
Next Report Date4th Aug 2022
Estimated EPS Next Report-2.70
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume96.52K
Shares Outstanding4.86K
Shares Float4.67M
Trades Count638
Dollar Volume257.83K
Avg. Volume1.99M
Avg. Weekly Volume161.08K
Avg. Monthly Volume2.28M
Avg. Quarterly Volume3.52M

Calithera Biosciences Inc. (NASDAQ: CALA) stock closed at 2.6 per share at the end of the most recent trading day (a 0.39% change compared to the prior day closing price) with a volume of 96.52K shares and market capitalization of 12.64M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 93 people. Calithera Biosciences Inc. CEO is Susan M. Molineaux.

The one-year performance of Calithera Biosciences Inc. stock is 21.6%, while year-to-date (YTD) performance is 290.86%. CALA stock has a five-year performance of -82.95%. Its 52-week range is between 2.31 and 49.8, which gives CALA stock a 52-week price range ratio of 0.61%

Calithera Biosciences Inc. currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 3.07, a price-to-sale (PS) ratio of 26.93, a price to cashflow ratio of 14.70, a PEG ratio of 2.32, a ROA of -140.28%, a ROC of -222.68% and a ROE of -253.05%. The company’s profit margin is -%, its EBITDA margin is -588.20%, and its revenue ttm is $9.75 Million , which makes it $0.10 revenue per share.

Of the last four earnings reports from Calithera Biosciences Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-2.70 for the next earnings report. Calithera Biosciences Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Calithera Biosciences Inc. is Moderate Buy (1.67), with a target price of $33.33, which is +1 181.92% compared to the current price. The earnings rating for Calithera Biosciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Calithera Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Calithera Biosciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.62, ATR14 : 0.24, CCI20 : 98.61, Chaikin Money Flow : -0.08, MACD : 0.63, Money Flow Index : 62.93, ROC : 1 200.00, RSI : 81.47, STOCH (14,3) : 90.78, STOCH RSI : 0.10, UO : 75.11, Williams %R : -9.22), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Calithera Biosciences Inc. in the last 12-months were: Christopher J. Molineaux (Buy at a value of $84 670), Jonathan G. Drachman (Buy at a value of $171 900), Keith Orford (Sold 51 810 shares of value $43 520 ), Susan M. Molineaux (Buy at a value of $84 670)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
3 (75.00 %)
3 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (33.33 %)
1 (25.00 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Strong Buy
1.50
Strong Buy
1.50

Calithera Biosciences Inc.

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm is functioned through the region of US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

CEO: Susan M. Molineaux

Telephone: +1 650 870-1000

Address: 343 Oyster Point Boulevard, South San Francisco 94080, CA, US

Number of employees: 93

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

52%48%

TipRanks News for CALA

News

Stocktwits